|Articles|August 2, 2016
OmniComm Signs Agreement with Research University
OmniComm Systems announced that it has signed an agreement with one of the top five medical research universities in the United States.
Advertisement
OmniComm Systems announced that it has signed an agreement with one of the top five medical research universities in the United States. The university plans to use OmniComm’s TrialMaster EDC and related services to conduct a series of clinical studies over a period of five years.
Read the full release here
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
eClinical Technology: Misconceptions, Challenges, and OpportunitiesSeptember 9th 2025
How Sponsors Can Modernize Tools to Support PhysiciansSeptember 9th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
AstraZeneca’s Tagrisso Shows Landmark Overall Survival Benefit in Non-Small Cell Lung Cancer
2
Phase III EMPOWER-Lung 3 Trial Confirms Five-Year Survival Benefit With Libtayo Plus Chemotherapy in NSCLC
3
Investigational OX40-Targetting T-Cell Therapy Shows Durable Efficacy Treating Atopic Dermatitis in Phase III Trial
4
Pfizer, BioNTech’s Comirnaty Shows Strong Immune Response in Phase III Trial for COVID-19
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
